Updating search results...

Search Resources

1 Result

View
Selected filters:
  • antineoplastic
The CDK7 inhibitor THZ1 fights gastrointestinal tumors by suppressing the oncogene c-KIT
Unrestricted Use
CC BY
Rating
0.0 stars

This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"Gastrointestinal stromal tumors (GISTs) are the most common malignant tumors in a type of gut tissue called mesenchyme. They’re caused by mutations that activate receptor tyrosine kinase (RTK) enzymes, and treatment with RTK inhibitors is initially successful, but over half of patients develop resistance, indicating a need for better treatments. Researchers recently investigated whether the drug THZ1, an inhibitor of the protein CDK7 that’s effective in other cancers, could help. They first confirmed that CDK7, which helps regulate the cell life cycle and gene transcription, was overexpressed in high-risk human GISTs. They also found that CDK7 overexpression predicted a poor outcome. However, low-dose THZ1 exerted pronounced anticancer effects in GIST cells both in vitro and in a mouse model. THZ1 also synergized with the RTK inhibitor imatinib to increase its efficacy..."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.

Subject:
Biology
Life Science
Material Type:
Diagram/Illustration
Reading
Provider:
Research Square
Provider Set:
Video Bytes
Date Added:
04/14/2023